SAN
DIEGO, Nov. 13, 2023 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused
biopharmaceutical company, today announced that is has resolved all
patent litigation related to lawsuits resulting from Abbreviated
New Drug Applications (ANDAs) brought by companies seeking approval
to market a generic version of INGREZZA® (valbenazine)
prior to the expiration of applicable Neurocrine patents. As
part of the resolution of these lawsuits, four companies have the
right to sell generic versions of INGREZZA in the United States beginning March 1, 2038, or earlier under certain customary
circumstances.
"These settlements reinforce our belief in the strength of the
INGREZZA intellectual property estate and provide clarity regarding
INGREZZA exclusivity. As an innovation-driven
biopharmaceutical company, we will continue to develop treatments
for under-addressed diseases and rely on a robust patent system to
protect that investment in innovation," said Darin Lippoldt, Chief Legal Office of Neurocrine
Biosciences.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused,
biopharmaceutical company with a simple purpose: to relieve
suffering for people with great needs but few options. We are
dedicated to discovering and developing life-changing treatments
for patients with under-addressed neurological, neuroendocrine and
neuropsychiatric disorders. The company's diverse portfolio
includes FDA-approved treatments for tardive dyskinesia, chorea
associated with Huntington's disease, Parkinson's disease,
endometriosis* and uterine fibroids*, as well as a robust pipeline
including multiple compounds in mid- to late-phase clinical
development across our core therapeutic areas. For three decades,
we have applied our unique insight into neuroscience and the
interconnections between brain and body systems to treat complex
conditions. We relentlessly pursue medicines to ease the burden of
debilitating diseases and disorders, because you deserve brave
science. For more information, visit neurocrine.com, and
follow the company on LinkedIn, X (formerly Twitter) and Facebook.
(*in collaboration with AbbVie)
NEUROCRINE BIOSCIENCES and NEUROCRINE are registered trademarks
of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark
of Neurocrine Biosciences, Inc.
Forward-Looking Statement
In addition to historical
facts, this press release contains forward-looking statements that
involve a number of risks and uncertainties. These statements
include, but are not limited to, statements regarding the potential
timing of generic entry. Among the factors that could cause actual
results to differ materially from those indicated in the
forward-looking statements include: competition from other
products, challenges to intellectual property, difficulties
inherent in the research and development process, adverse
litigation or government action, changes to laws and regulations
applicable to our industry and other risks described in the
Company's periodic reports filed with the Securities and Exchange
Commission, including without limitation the Company's quarterly
report on Form 10-Q for the quarter ended September 30, 2023. Neurocrine Biosciences
disclaims any obligation to update the statements contained in this
press release after the date hereof.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-settlement-of-ingrezza-abbreviated-new-drug-application-anda-litigation-301985856.html
SOURCE Neurocrine Biosciences, Inc.